Physician profile
Harsh Govil
NPI 1568671782
$19,423.16
in general payments reported to CMS, 2019-2025
40 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $186 · 2021: $355 · 2022: $1,604 · 2023: $1,414 · 2024: $2,183 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $4,673 · Travel and Lodging: $992 · Education: $20.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,000.00 |
| Food and Beverage | $4,672.81 |
| Travel and Lodging | $992.28 |
| Education | $20.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Milestone Scientific INC. | $10,000.00 | 2025 | |
| Boston Scientific Corporation | $3,402.51 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, General - Therapies |
| Medtronic, INC. | $1,226.83 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Medtronic USA, INC. | $640.21 | 2019 | |
| Curonix LLC | $593.92 | 2022-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Si-Bone, INC. | $557.74 | 2022-2024 | |
| Nevro Corp. | $498.11 | 2019-2024 | Senza |
| Forte Bio-Pharma LLC | $398.70 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Stimwave Technologies Incorporated | $276.69 | 2022 | |
| Collegium Pharmaceutical, INC. | $220.59 | 2019-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $182.05 | 2025 | Prospera |
| Vertex Pharmaceuticals Incorporated | $133.96 | 2024-2025 | |
| Vertos Medical, INC. | $132.26 | 2022 | |
| Scilex Pharmaceuticals INC. | $127.43 | 2022-2025 | Ztlido |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Govil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.